Blair William & Co. IL decreased its position in Psychemedics Corp. (NASDAQ:PMD) by 2.9% during the 3rd quarter, Holdings Channel reports. The firm owned 106,733 shares of the company’s stock after selling 3,150 shares during the period. Blair William & Co. IL’s holdings in Psychemedics were worth $2,008,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Quantum Capital Management lifted its stake in Psychemedics by 7.0% in the second quarter. Quantum Capital Management now owns 50,521 shares of the company’s stock worth $972,000 after acquiring an additional 3,316 shares during the period. North Star Investment Management Corp. lifted its stake in Psychemedics by 6.1% in the third quarter. North Star Investment Management Corp. now owns 81,277 shares of the company’s stock worth $1,529,000 after acquiring an additional 4,654 shares during the period. Seizert Capital Partners LLC lifted its stake in Psychemedics by 30.3% in the third quarter. Seizert Capital Partners LLC now owns 30,179 shares of the company’s stock worth $568,000 after acquiring an additional 7,015 shares during the period. Crawford Investment Counsel Inc. lifted its stake in Psychemedics by 4.0% in the third quarter. Crawford Investment Counsel Inc. now owns 255,284 shares of the company’s stock worth $4,802,000 after acquiring an additional 9,743 shares during the period. Finally, Deprince Race & Zollo Inc. lifted its stake in Psychemedics by 388.7% in the third quarter. Deprince Race & Zollo Inc. now owns 288,147 shares of the company’s stock worth $5,420,000 after acquiring an additional 229,180 shares during the period. Hedge funds and other institutional investors own 57.37% of the company’s stock.

Separately, ValuEngine raised Psychemedics from a “hold” rating to a “buy” rating in a research note on Friday, October 12th.

Shares of PMD stock opened at $16.33 on Friday. Psychemedics Corp. has a 52 week low of $16.11 and a 52 week high of $22.88. The firm has a market capitalization of $93.68 million, a P/E ratio of 19.11 and a beta of 0.75. The company has a quick ratio of 2.73, a current ratio of 2.73 and a debt-to-equity ratio of 0.09.

Psychemedics (NASDAQ:PMD) last announced its quarterly earnings results on Tuesday, October 23rd. The company reported $0.23 EPS for the quarter. Psychemedics had a return on equity of 26.58% and a net margin of 14.24%. The company had revenue of $11.02 million during the quarter.

The firm also recently declared a quarterly dividend, which was paid on Monday, November 12th. Investors of record on Friday, November 2nd were paid a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a yield of 4.41%. The ex-dividend date was Thursday, November 1st.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/12/07/psychemedics-corp-pmd-stake-lessened-by-blair-william-co-il.html.

Psychemedics Profile

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time.

See Also: Stock Symbols, CUSIP and Other Stock Identifiers

Want to see what other hedge funds are holding PMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Psychemedics Corp. (NASDAQ:PMD).

Institutional Ownership by Quarter for Psychemedics (NASDAQ:PMD)

Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.com's FREE daily email newsletter.